Phase 1Data readout

SEP-479 (PTH1R Agonist)

Hypoparathyroidism

SEPNSepterna

Expected catalystMarch 31, 2027Company guidance: Mar 31, 2027

Catalyst overview

Event details

Drug or asset: SEP-479 (PTH1R Agonist)
Development stage: Phase 1
Event type: Data readout
Indication: Hypoparathyroidism

Research summary

What is being tracked?

This catalyst tracks a Phase 1 data readout for SEP-479 (PTH1R Agonist) in Hypoparathyroidism. The expected timing is based on the latest available company guidance and may change.

Development notes

03/09/26:- IND-enabling complete. Phase 1 trial in hypoparathyroidism initiation planned H1 2026. 05/11/26:- Ph1 trial initiated April 2026. SAD/MAD data in healthy volunteers expected late 2026 or early 2027. 08/10/26:- Ph1 ongoing; SAD/MAD data now expected Q1 2027 after 14-day MAD dosing.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source